Rush to protect lucrative antibody patents kicks into gear

A government court choice has left colleges and organizations attempting to protect licensed innovation rights worth billions.

US? colleges and biotechnology organizations are scrambling to ensure a portion of their most important resources: licenses on antibodies. These invulnerable framework atoms shape the premise of medications that rake in about US$100 billion every year. In any case, securing licensed innovation rights to antibodies has turned out to be considerably more troublesome, under rules discharged in February by the US Patent and Trademark Office (USPTO). 

The amended guidelines come after a government court choice last October limited the extent of immune response licenses